多发性骨髓瘤
医学
抗体
抗体-药物偶联物
抗原
药品
药物开发
单克隆抗体
癌症研究
免疫学
药理学
肿瘤科
作者
Christopher Ferreri,Hans C. Lee
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2022-11-01
卷期号:28 (6): 488-495
被引量:1
标识
DOI:10.1097/ppo.0000000000000628
摘要
Antibody-drug conjugates (ADCs) have emerged as a treatment option for patients with relapsed/refractory multiple myeloma with the regulatory approval of the first-in-class B-cell maturation antigen (BCMA) ADC belantamab mafodotin. Other BCMA and non-BCMA ADCs are currently in clinical development. Whereas ADCs allow antigen-specific delivery of a chemomoiety to myeloma cells, on-target and off-target effects related to antigen target, antibody, linker, and chemomoiety can also limit these approaches. We review the clinical development of belantamab mafodotin and ongoing efforts to enhance its efficacy while mitigating ocular toxicity. The landscape of other ADCs being evaluated clinically in patients with multiple myeloma will also be reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI